Applied Therapeutics, Inc. (APLT)
$
0.1
Key metrics
Financial statements
Free cash flow per share
-0.5966
Market cap
14.9 Million
Price to sales ratio
14.8630
Debt to equity
-4.4563
Current ratio
0.9621
Income quality
4.7881
Average inventory
0
ROE
-0.6563
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative products aimed at addressing cardiovascular diseases, galactosemia, and complications associated with diabetes. The company’s lead product candidate, AT-007, has successfully completed phase 1/2 trials for the treatment of galactosemia in healthy adults and is currently being evaluated in pediatric studies for the same condition. Furthermore, AT-007 is under investigation for treating sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. In addition to AT-007, Applied Therapeutics is advancing AT-001, which is presently undergoing phase III clinical trials intended for diabetic cardiomyopathy and diabetic peripheral neuropathy. The company also has preclinical candidates, including AT-003 for diabetic retinopathy and AT-104, a PI3K inhibitor targeting T Cell Acute Lymphoblastic Leukemia in hematological oncology. As for its financial performance, the earnings per share (EPS) is reported at -$0.76 indicating the company's profitability on a per-share basis. The operating expenses amount to $56,010,000.00 encompassing various operational costs incurred. Furthermore, the company reported an income before tax of -$105,624,000.00 showcasing its pre-tax profitability. The diluted EPS stands at -$0.76 accounting for potential share dilution, while the net income ratio is -$232.14 reflecting the company's profitability margin. With a market capitalization of $14,862,969.00 Applied Therapeutics is classified as a small-cap player in the biopharmaceutical landscape. The stock is affordable at $0.43 making it suitable for budget-conscious investors. Additionally, the stock has a high average trading volume of 15,797,213.00 which indicates strong liquidity in the market. As a key player in the Biotechnology industry, the company contributes significantly to the overall market landscape, while belonging to the Healthcare sector, driving ongoing innovation and growth within the healthcare field.
What is Applied Therapeutics, Inc. (APLT)'s stock forecast?
Analysts predict Applied Therapeutics, Inc. stock to fluctuate between $0.09 (low) and $1.50 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Applied Therapeutics, Inc.'s market capitalization?
As of 2026-02-02, Applied Therapeutics, Inc.'s market cap is $14,862,969, based on 144,300,674 outstanding shares.
How does Applied Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Applied Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Applied Therapeutics, Inc. (APLT) stock?
To buy Applied Therapeutics, Inc. (APLT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for APLT. Place an order (Market, Limit, etc.).
What is the best time to invest in Applied Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Applied Therapeutics, Inc. perform in the last earnings report?
Revenue: $455,000 | EPS: -$0.76 | Growth: -46.48%.
Where can I find Applied Therapeutics, Inc.'s investor relations reports?
Visit https://www.appliedtherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Applied Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Applied Therapeutics, Inc. stock?
All-time high: $19.14 (2021-10-14) | All-time low: $0.09 (2026-01-12).
What are the key trends affecting Applied Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; “Applied”), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Deh.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Therapeutics, Inc. (NASDAQ: APLT) to Cycle Group Holdings Limited for $0.088 per share in cash plus one non-transferrable contingent value right entitling the holder to receive potential additional payments under certain conditions is fair to Applied shareholders. Halper Sadeh encourages Applied shareholders to click here to learn more about their legal rights and options or co.
globenewswire.com
Applied Therapeutic's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases Applied Therapeutic's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases
zacks.com
Applied Therapeutics (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
globenewswire.com
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced key appointments to its executive leadership team with the promotions of Evan Bailey, MD, to Chief Medical Officer (CMO), effective June 15, 2025, and Dottie Caplan to Executive Vice President (EVP), Patient Advocacy and Government Affairs.
globenewswire.com
- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting
globenewswire.com
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130443&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130340&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130271&wire=1 or contact Joseph E. Levi, Esq.
See all news
